Recombinant VEGF (Bevacizumab Biosimilar) antibody

Catalog No. ABIN7200653

This Mouse Monoclonal antibody specifically detects VEGF (Bevacizumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant VEGF (Bevacizumab Biosimilar) antibody (ABIN7200653)

Target: VEGF (Bevacizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-VEGF (Bevacizumab Biosimilar) Antibody

Purpose: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody

Specificity: The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.

Characteristics: Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for VEGF (Bevacizumab Biosimilar)

Target: VEGF (Bevacizumab Biosimilar)

Target Type: Biosimilar

Background: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.